Antimicrobial Resistance Trends in Urinary Tract Infections in 6 African Countries - Report - MDSpire

Antimicrobial Resistance Trends in Urinary Tract Infections in 6 African Countries

  • By

  • Lala Fanomezantsoa Rafetrarivony

  • Félix Cheysson

  • Dissou Affolabi

  • Cheikh Fall

  • Faridath Massou

  • Kaotar Nayme

  • Minone Rosanne Ngome

  • Andriniaina Rakotondrasoa

  • Thomas Bovagnet

  • Aboubakr Khazaz

  • Hugues Sanke-Waïgana

  • Gilles Stéphane Landry Ngaya

  • Jean-Robert Mbecko

  • Anne-Lise Beaumont

  • Chiara Crestani

  • Yakhya Dieye

  • Babacar Ndiaye

  • Abdou Diop

  • Pierrette Landrie Simo Tchuinte

  • Ariane Nzouankeu

  • Arsène Godlove Djoko Nono

  • Dimitri Rasoloson

  • Frédérique Randrianirina

  • Elisoa Hariniaina Ratsima

  • Lovasoa Ramparany

  • Sébastien Breurec

  • Tania Crucitti

  • Sylvain Brisse

  • Bich-Tram Huynh

  • July 9, 2026

  • 0 min

Share

Trends in Antimicrobial Resistance for Urinary Tract Infections Across Six African Nations

Overview

This study investigates antimicrobial resistance (AMR) trends in E. coli and K. pneumoniae isolates from urine samples across six African countries over a decade.

Background

Antimicrobial resistance is a critical global health issue, particularly in Africa, where factors such as antibiotic misuse and under-resourced healthcare systems exacerbate the problem. UTIs, caused primarily by E. coli and K. pneumoniae, are prevalent and can lead to severe morbidity.

Data Highlights

No numerical data was provided in the source material.

Key Findings

  • AMR trends were analyzed for E. coli and K. pneumoniae from urine samples over 10 years.
  • Data were collected from clinical laboratories in Benin, Cameroon, CAR, Madagascar, Morocco, and Senegal.
  • Resistance mechanisms such as extended-spectrum β-lactamases (ESBLs) and carbapenemases were noted in the pathogens.
  • Access to novel antibiotics is limited in Africa.
  • Monitoring resistance trends is crucial for understanding AMR evolution.

Clinical Implications

Healthcare professionals should be aware of the rising AMR rates in common uropathogens.

Conclusion

The study highlights the need for tracking AMR trends in the context of urinary tract infections in Africa.

Related Resources & Content

  1. WHO, Global Antimicrobial Resistance Surveillance Report, 2023 -- Antimicrobial Resistance Overview
  2. Drugs - Real World Outcomes, 2018 -- Antimicrobial Resistance Trends in Bacterial Isolates from Urogenital Samples
  3. Open Forum Infectious Diseases, 2021 -- Trends in Antimalarial Partner Drug Resistance Markers
  4. International Journal of Infectious Diseases, 2026 -- Erosion of empirical therapy in community-acquired urinary tract infections
  5. International Journal of Infectious Diseases — Trends in antimicrobial resistance associated with gastrointestinal tract infections in the UAE: A comprehensive retrospective surveillance 13-year (2010-2022) study
  6. WHO Global Antimicrobial Resistance and Use Surveillance System (GLASS) 2025 report
  7. Act now: Protect our present, secure our future | WHO
  8. EAU Guidelines on Urological Infections 2026
  9. Global antibiotic resistance surveillance report 2025
  10. IDSA 2025 Guideline Update on Complicated Urinary Tract Infections
  11. Efficacy and in vitro activity of gepotidacin against bacterial uropathogens, including drug-resistant phenotypes, in females with uncomplicated urinary tract infections: results from two global, pivotal, phase 3 trials (EAGLE-2 and EAGLE-3) | Antimicrobial Agents and Chemotherapy
  12. FDA Approves New Treatment for Uncomplicated Urinary Tract Infections | FDA
  13. Antimicrobial resistance of Enterobacterales in Central Africa: a systematic review and meta-analysis | Communications Medicine

Original Source(s)

Antimicrobial Resistance Trends in Urinary Tract Infections in 6 African Countries

  • by Lala Fanomezantsoa Rafetrarivony, Félix Cheysson, Dissou Affolabi, Cheikh Fall, Faridath Massou, Kaotar Nayme, Minone Rosanne Ngome, Andriniaina Rakotondrasoa, Thomas Bovagnet, Aboubakr Khazaz, Hugues Sanke-Waïgana, Gilles Stéphane Landry Ngaya, Jean-Robert Mbecko, Anne-Lise Beaumont, Chiara Crestani, Yakhya Dieye, Babacar Ndiaye, Abdou Diop, Pierrette Landrie Simo Tchuinte, Ariane Nzouankeu, Arsène Godlove Djoko Nono, Dimitri Rasoloson, Frédérique Randrianirina, Elisoa Hariniaina Ratsima, Lovasoa Ramparany, Sébastien Breurec, Tania Crucitti, Sylvain Brisse, Bich-Tram Huynh

  • July 9, 2026

Related Content

Immunogenicity and safety of primary three-dose series with diphtheria, tetanus and pertussis (acellular, three components) combined vaccine, adsorbed in 3 months infants

Impaired IFN-γ-mediated innate and adaptive immunity in Coffin-Siris syndrome type 2: immunological insights from a patient with a recurrent ARID1A mutation

Case Report: immune checkpoint inhibitor-associated aseptic meningitis in lung cancer: two cases illustrating an exclusion-based diagnosis approach and stepwise immunosuppressive treatment